Ensysce Biosciences (NASDAQ:ENSC) is a clinical stage company that is developing novel opioids that provide the needed pain relief, while greatly limiting the potential for abuse and overdoses that ...
Ensysce Biosciences shares are trading lower by 30% during Thursday's session. The company announced a $5 million registered direct offering and concurrent private placement. Post-Labor Day Trading ...
Ensysce Biosciences Inc (NASDAQ:ENSC) completed PF614-MPAR-101, a clinical study examining the company's first pain medication with overdose protection, PF614-MPAR. The final Part B of the study ...
Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...
Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results